As an important policy instrument for promoting the high-quality development of the real economy, government-guided funds possess unique advantages in steering long-term capital allocation and fostering patient capital. Using GEM Listed Companies from 2012 to 2023 as the research sample, this paper empirically investigates the impact of government-guided funds on patient capital and explores its heterogeneity. The findings demonstrate that government-guided funds significantly promote the growth of patient capital, and the conclusions remain robust after multiple robustness checks. The study further reveals that government-guided funds enhance patient capital through three channels: reducing Type II agency costs, strengthening market power, and improving total factor productivity. Moreover, firms' innovation level negatively moderates the relationship between government-guided funds and patient capital. Heterogeneity analysis shows that government-guided funds play a stronger role in cultivating patient capital when firms have executives with overseas backgrounds, when the roles of chairman and CEO are separated, when the level of financing constraints is higher, and when analyst coverage is relatively low.
扫码关注我们
求助内容:
应助结果提醒方式:
